Myeloproliferative neoplasms: from origins to outcomes
Open Access
- 7 December 2017
- journal article
- review article
- Published by American Society of Hematology in Blood
- Vol. 130 (23), 2475-2483
- https://doi.org/10.1182/blood-2017-06-782037
Abstract
Substantial progress has been made in our understanding of the pathogenetic basis of myeloproliferative neoplasms. The discovery of mutations in JAK2 over a decade ago heralded a new age for patient care as a consequence of improved diagnosis and the development of therapeutic JAK inhibitors. The more recent identification of mutations in calreticulin brought with it a sense of completeness, with most patients with myeloproliferative neoplasm now having a biological basis for their excessive myeloproliferation. We are also beginning to understand the processes that lead to acquisition of somatic mutations and the factors that influence subsequent clonal expansion and emergence of disease. Extended genomic profiling has established a multitude of additional acquired mutations, particularly prevalent in myelofibrosis, where their presence carries prognostic implications. A major goal is to integrate genetic, clinical, and laboratory features to identify patients who share disease biology and clinical outcome, such that therapies, both existing and novel, can be better targeted.Keywords
This publication has 108 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2The Journal of Experimental Medicine, 2012
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Cancer-associated IDH1 mutations produce 2-hydroxyglutarateNature, 2009
- JAK2Exon 12 Mutations in Polycythemia Vera and Idiopathic ErythrocytosisThe New England Journal of Medicine, 2007
- Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosisBlood, 2006
- The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiationProceedings of the National Academy of Sciences of the United States of America, 2006
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia veraNature, 2005